Inozyme Pharma to Present at the Jefferies Global Healthcare Conference

Rhea-AI Summary

Inozyme Pharma (Nasdaq: INZY), a clinical-stage biopharmaceutical company specializing in rare diseases, announced that its CEO and Chairman, Doug Treco, Ph.D., will present at the Jefferies Global Healthcare Conference. The presentation is scheduled for Thursday, June 6, 2024, from 12:30 to 12:55 pm ET. A live webcast will be available on the Investor Relations section of Inozyme's website, with a replay accessible for a time.

Positive

• Inozyme's participation in a prestigious conference could enhance visibility and investor interest.
• The CEO's presentation might provide valuable insights into the company's strategy and progress.
• Availability of a live webcast and replay ensures broader access to the presentation.

Negative

• The press release lacks concrete financial or clinical data updates.
• Absent new product or trial announcements may disappoint investors looking for substantive progress.

BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Doug Treco, Ph.D., CEO and Chairman of Inozyme, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 from 12:30-12:55 pm ET.

A live webcast of the presentation can be accessed from the Investor Relations section of Inozyme’s website under events, where a replay of the event will also be available for a limited time.

About Inozyme Pharma

Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. Inozyme is developing INZ-701, an enzyme replacement therapy, to address pathologic mineralization and intimal proliferation, which can drive morbidity and mortality in these severe diseases. INZ-701 is currently in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency and calciphylaxis.

For more information, please visit https://www.inozyme.com/ or follow Inozyme on LinkedIn, X, and Facebook.

Contacts

Investors:
Inozyme Pharma
Stefan Riley, Senior Director of IR and Corporate Communications
(857) 330-8871
stefan.riley@inozyme.com

Media:
SmithSolve
Matt Pera
(973) 886-9150
matt.pera@smithsolve.com

FAQ

When will Inozyme Pharma present at the Jefferies Global Healthcare Conference?

Inozyme Pharma will present on Thursday, June 6, 2024, from 12:30 to 12:55 pm ET.

How can I watch Inozyme Pharma's presentation at the Jefferies Global Healthcare Conference?

A live webcast of the presentation will be available on the Investor Relations section of Inozyme's website.

What is the stock ticker for Inozyme Pharma?

The stock ticker for Inozyme Pharma is INZY.

Who is presenting for Inozyme Pharma at the Jefferies Global Healthcare Conference?

Doug Treco, Ph.D., the CEO and Chairman of Inozyme Pharma, will be presenting.

Will there be a replay available for Inozyme Pharma's presentation at the Jefferies Global Healthcare Conference?

Yes, a replay of the event will be available for a time on Inozyme's website.